China's First COVID-19 Virus Vaccine Patent Granted to CanSino Bio
The China National Intellectual Property Administration (CNIPA) granted on September 11, 2020 what may be the first patent covering a vaccine for the COVID-19 virus. The patent published under number CN111218459B.
The Institute of Military Medicine, Chinese Academy of Military Sciences in conjunction with CanSinoBIO, a Chinese vaccine maker, filed application CN202010193587.8 on March 18, 2020 and is entitled “A new recombinant coronavirus vaccine using human replication-deficient adenovirus as a vector.”
The patent is based on research earlier published in the Lancet showing their Ad5 vectored COVID-19 vaccine “is tolerable and immunogenic at 28 days post-vaccination.” Per the Wall Street Journal, China’s military has already approved the use of CanSino’s vaccine before the completion of large-scale final testing, usually known as Phase 3 trials.